8-K: Vivos Therapeutics Secures $4.6M in Warrant Exercise

Vivos Therapeutics completed an inducement transaction, generating $4.6 million in gross proceeds from warrant exercises and issuing new warrants.

Summary

• Vivos Therapeutics, Inc. (VVOS) completed an inducement transaction on January 20, 2026, with an institutional investor.
• The investor exercised existing warrants for 1,982,356 shares of common stock at a reduced exercise price of $2.34 per share, generating approximately $4.6 million in gross proceeds for the company.
• In consideration, Vivos issued two new unregistered common stock purchase warrants to the investor: a Series A warrant for 1,982,356 shares expiring in five years (January 21, 2031) and a Series B warrant for 1,982,356 shares expiring in 24 months (January 20, 2028), both with an exercise price of $2.09 per share.
• The company intends to use the net proceeds for general working capital and corporate purposes.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee (approximately $322,000), a 1.0% management fee (approximately $46,000), and warrants to purchase 138,765 shares at an exercise price of $2.925.

Sentiment

Score: 3

Explanation: While the company successfully raised $4.6 million in immediate cash, the transaction involved significant dilution through reduced exercise prices for existing warrants and the issuance of a large number of new warrants and placement agent warrants. The high cost of capital and ongoing need for financing, as evidenced by the inducement and future contemplated raise, suggest underlying financial challenges.

Positives

• Secured approximately $4.6 million in gross proceeds, improving working capital.
• Successfully induced an institutional investor to exercise existing warrants for cash.
• The transaction provides immediate cash flow for general corporate purposes.

Negatives

• Existing warrants were exercised at a reduced price of $2.34 per share, significantly lower than their original exercise prices ($3.83 and $5.05), indicating a dilution of potential capital from previous warrant agreements.
• Significant dilution potential from the issuance of 3,964,712 new inducement warrants and 138,765 placement agent warrants, totaling 4,103,477 new potential shares.
• Payment of substantial fees to the placement agent: approximately $322,000 cash fee, approximately $46,000 management fee, and 138,765 placement agent warrants.
• Restrictions on future equity issuances and variable rate transactions for specified periods, limiting financial flexibility.
• The new warrants have an exercise price of $2.09, which is lower than the reduced exercise price of $2.34 for the old warrants, suggesting the market price might be below $2.34 or the company needed to make the new warrants attractive.

Risks

• Future dilution if the new inducement warrants and placement agent warrants are exercised.
• Potential for liquidated damages if the company fails to timely deliver warrant shares upon future exercises or remove restrictive legends.
• Market perception of repeated warrant inducement transactions and associated dilution.
• The company's stock price may not reach the exercise prices of the new warrants, rendering them unexercised and not providing further capital.
• The company is prohibited from certain equity issuances and variable rate transactions for specific periods, which could limit its ability to raise capital quickly if needed.

Future Outlook

The company plans to use the net proceeds from the warrant exercise for general working capital and corporate purposes. It is committed to filing a registration statement for the resale of the newly issued inducement warrant shares by February 14, 2026, and aims for it to become effective by March 16, 2026 (or April 15, 2026, if subject to SEC review). The company also has restrictions on future equity issuances and variable rate transactions for specified periods. A potential future financing of up to $5.5 million with Seneca Partners is also mentioned as an exempt issuance.

Industry Context

This transaction is a common method for companies, particularly those with ongoing capital needs or lower stock prices, to raise funds by incentivizing existing warrant holders to exercise. The issuance of new warrants as an inducement is a typical feature in such agreements, often leading to further potential dilution but also providing future capital opportunities if the stock price appreciates. The involvement of H.C. Wainwright & Co., LLC as a placement agent is standard for such private placement transactions in the small-cap and growth company space.

Comparison to Industry Standards

• The use of warrant inducement to raise capital is a common practice for companies, especially those with a need for immediate cash and outstanding warrants that are out-of-the-money or near-the-money.
• The fees paid to H.C. Wainwright & Co., LLC (7.0% cash fee, 1.0% management fee, and 7.0% warrant coverage) are generally within the range for placement agent services in small-cap private placements, though on the higher side, reflecting the perceived risk or difficulty in raising capital.
• The anti-dilution, cashless exercise, and beneficial ownership limitations in the warrants are standard protective provisions for institutional investors.
• The Black-Scholes put right in the Series A Inducement Warrant in case of a Fundamental Transaction is a strong protective feature for the holder, less common in standard warrants but sometimes seen in more complex financing arrangements.

Stakeholder Impact

• Shareholders: Experience immediate dilution from the reduced exercise price of existing warrants and potential future dilution from the exercise of new inducement warrants and placement agent warrants. The capital raise provides liquidity but at a cost.
• Creditors: Improved liquidity from the capital raise may reduce immediate credit risk.
• Employees/Customers/Suppliers: No direct impact mentioned, but improved working capital could support ongoing operations.

Next Steps

• File a registration statement for the resale of the Inducement Warrant Shares by February 14, 2026.
• Use best efforts to cause the Resale Registration Statement to become effective by March 16, 2026 (or April 15, 2026 if subject to SEC review).
• Maintain listing of Common Stock on Nasdaq Capital Market and apply to list new warrant shares.
• Comply with restrictions on future equity issuances until February 19, 2026.
• Comply with prohibition on variable rate transactions for six months from the effective date of the Resale Registration Statement.
• Potentially pursue an unsecured short-term bridge note and equity private placement financing of up to $5.5 million with Seneca Partners.

Key Dates

Recommendation

The transaction, while providing immediate capital, comes at a significant cost in terms of dilution and future potential dilution. The need to induce warrant exercises at a reduced price, coupled with the issuance of new warrants at an even lower exercise price, suggests a struggling stock price and ongoing capital needs. The high fees paid to the placement agent further erode the value. These factors indicate a challenging financial position and potential for continued downward pressure on the stock due to future exercises and the overall cost of capital.

Keywords

Vivos Therapeutics, VVOS, warrant exercise, capital raise, private placement, common stock, inducement agreement, H.C. Wainwright, dilution, working capital, equity financing, SEC filing, Form 8-K